Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Szu-Yuan Wu; Wan-Ming Chen; Yi-Chan Chen; Ming-Feng Chiang; Ming-Che Lee; Ruey-Shyang Soong

doi:10.1016/j.diabet.2022.101393

Effects of H1-Antihistamines on hepatocellular carcinoma risk in patients with type 2 diabetes mellitus

Diabetes Metab. 2023 Jan;49(1):101393. doi: 10.1016/j.diabet.2022.101393. Epub 2022 Sep 25.

Authors

Szu-Yuan Wu¹, Wan-Ming Chen², Yi-Chan Chen³, Ming-Feng Chiang⁴, Ming-Che Lee⁵, Ruey-Shyang Soong⁶

Affiliations

¹ 1Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan; Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan; Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan; Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan; Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan; Centers for Regional Anesthesia and Pain Medicine, Taipei Municipal Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
² 1Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City, Taiwan; Artificial Intelligence Development Center, Fu Jen Catholic University, New Taipei City, Taiwan.
³ Department of General Surgery, Chang Gung Memorial Hospital, Keelung, Taiwan.
⁴ Division of Gastroenterology and Hepatology, Department of Internal Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan 265, Taiwan.
⁵ Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; College of Medicine, Taipei Medical University, Taipei, Taiwan.
⁶ Department of Surgery, Taipei Municipal Wanfang Hospital, Taipei, Taiwan; College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address: kodlp62@gmail.com.

PMID: 36170945
DOI: 10.1016/j.diabet.2022.101393

Abstract

Purpose: H1-antihistamines (AHs) may exert protective effects against cancer. We investigated the association of AH use with hepatocellular carcinoma (HCC) risk in type 2 diabetes mellitus (T2DM) patients without hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

Methods: The data of patients with T2DM enrolled from Taiwan's National Health Insurance Research Database were examined for the period of January 1, 2008, to December 31, 2018. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the AH use-HCC risk association.

Results: After 1:1 propensity score matching was performed, the two cohorts were each divided into AH users (n = 47,990) and nonusers (n = 47,990). The risk of HCC was significantly lower in AH users than in AH nonusers (adjusted hazard ratio [aHR]: 0.55 95% confidence interval [95% CI], 0.46 to 0.67; IRR: 0.70; 95% CI, 0.60 to 0.84), respectively. The dose-response relationship between AH use and HCC risk was also observed (aHRs: 0.58, 0.56, 0.50, and 0.41 for 28-35, 36-49, 50-77, and >77 cumulative defined daily doses of AH, respectively).

Conclusion: AH use can reduce HCC risk in T2DM patients without HBV or HCV infection in a dose-dependent manner.

Keywords: H1-Antihistamines; Hepatocellular Carcinoma; Type 2 Diabetes Mellitus; dose-dependent; incidence rate ratio.

MeSH terms

Carcinoma, Hepatocellular* / epidemiology
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Diabetes Mellitus, Type 2* / epidemiology
Hepatitis C* / complications
Hepatitis C* / drug therapy
Hepatitis C* / epidemiology
Histamine Antagonists
Humans
Liver Neoplasms* / epidemiology

Substances

Histamine Antagonists